Part I: Liver function in oncology: biochemistry and beyond (Q37326848)

19 August 2017

1 reference

title

Part I: Liver function in oncology: biochemistry and beyond (English)

1 reference

19 August 2017

Kathryn M Field

1

1 reference

19 August 2017

Chris Dow

series ordinal

2

1 reference

19 August 2017

Michael Michael

series ordinal

3

1 reference

19 August 2017

language of work or name

1 reference

1 November 2008

1 reference

Lancet Oncology Commission

19 August 2017

published in

1 reference

19 August 2017

volume

9

1 reference

19 August 2017

issue

11

1 reference

19 August 2017

page(s)

1092-1101

1 reference

Isoforms of alanine aminotransferases in human tissues and serum--differential tissue expression using novel antibodies

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

TIPS for Budd-Chiari Syndrome: Long-Term Results and Prognostics Factors in 124 Patients

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

A model to predict survival in patients with end-stage liver disease

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Liver enzyme alteration: a guide for clinicians.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Updated definitions of healthy ranges for serum alanine aminotransferase levels

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Is there room for improvement in adverse event reporting in the era of targeted therapies?

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Stauffer's syndrome variant associated with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Liver damage in patients with colony-stimulating factor-producing tumors

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Regulation of drug transporters during infection and inflammation.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Effects of smoking on the pharmacokinetics of erlotinib

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Management of cancer in the older person: a practical approach

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Veno-occlusive disease of the liver after hemopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

HEPATOTOXICITY OF MERCAPTOPURINE

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Hepatotoxicity due to chlorambucil; report of a case

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Effect of liver failure on the pharmacokinetics of cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols: a clinical-pathologic study of 33 patients

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Hepatic veno-occlusive disease due to DTIC.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Hepatotoxicity of actinomycin-D

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Etoposide (VP 16-213) induced hepatitis. Report of three cases following standard-dose treatments

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Liver pathology following hepatic arterial infusion chemotherapy. Hepatic toxicity with FUDR

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Fatal cholestatic liver failure associated with gemcitabine therapy

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Imatinib-induced fatal acute liver failure

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Imatinib mesylate (gleevec) hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Clinical toxicity of interferons in cancer patients: a review

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Ten year's experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Hepatotoxicity of chemotherapy

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the national cancer institute organ dysfunction working group

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Taxanes: a new class of antitumor agents.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Topoisomerase I inhibitors: topotecan and irenotecan

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

The effect of malignant effusions on methotrexate disposition

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Topoisomerase I inhibitors. An overview of the camptothecin analogs.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(08)70279-1

7 January 2021

10.1016/S1470-2045(08)70279-1

Identifiers

DOI

1 reference

19 August 2017

1 reference